

# Expand Your Clinical Trial Population with Our HRD Signature (HRDsig)

HRDsig can identify more patients, including those with or without relevant HRR gene mutations, that may respond to therapy.

2023 PUBLICATION IN OVARIAN CANCER<sup>1</sup>



39%

of patients were HRDsig+ compared to 18% of patients who were BRCA1/2+.



Mutation+



Wild-Type with BRCAness



HRDsig has validation across tumor types that can support clinical trials and future CDx development for tumor-specific or pan-tumor applications.



Ovarian



Prostate



Breast



Pancreas



Lung

SEE DATA EXAMPLES ON BACK



6%

Prevalence of HRDsig+ in a pan-tumor setting.<sup>2</sup>

HRDsig identified 18% more HRD positive results than Myriad GIS in an ovarian cancer study using abstracted results from the Flatiron Health-Foundation Medicine CGDB (n=156).<sup>3</sup>




93%

overall percent agreement with Myriad GIS for tissue specimens collected within 90 days of each other.<sup>3</sup>

Foundation Medicine's HRDsig biomarker is now available for investigational use on the clinical trial assay based on FoundationOne®CDx, our tissue-based CGP test.<sup>4</sup>




### DATA EXAMPLE: OVARIAN CANCER<sup>1</sup>



HRDsig+ is detected in 39% of patients overall, with 58% of these patients being BRCA1/2wt



### DATA EXAMPLE: BREAST CANCER<sup>5</sup>



## HRDsig is a comprehensive, scar-based signature with diverse potential use cases for therapy development.

- 1 Better performance than gLOH** (sensitivity and specificity)<sup>2</sup> and designed for use **across tumor types**
- 2 Captures non-genomic mechanisms** of HRD, like *BRCA1* promoter methylation
- 3 Detects different HRD phenotypes and can identify monoallelic HRR passenger mutations as HRDsig-**



HRDsig was developed with the use of machine-learning methods and further explored using our FoundationCore<sup>®</sup> database, which contains comprehensive, de-identified genomic data from >600,000 patient samples.<sup>3</sup>



HRDsig can also be explored for research collaborations using blood or plasma samples—please contact us for more details.



HRD = Homologous Recombination Deficiency. HRR = Homologous Recombination Repair. gLOH = Genomic Loss of Heterozygosity

#### References:

- Richardson et al. 2023;41(16\_suppl):5583-5583. doi: [https://doi.org/10.1200/jco.2023.41.16\\_suppl.5583](https://doi.org/10.1200/jco.2023.41.16_suppl.5583).
- Antonarakis E, et al. Cancer Res. 2022;82(12\_suppl):1249-1249.
- Data on file, Foundation Medicine, Inc. 2022.
- For Investigational Use Only. The performance characteristics of this product have not been established.
- Batalini et al. 2023 JCO Precis Oncol 7:32300091. doi: <https://doi.org/10.1200/PO.23.00091>